Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guobang PharmaSHSE:605507 +0.06%88 PB Ratio is 1.46 as of Jul. 30, 2026, which is 9% below its 10-year median of 1.61. GuruFocus rates SHSE:605507 with a GF Score™ of 88/100 and a GF Value™ of ¥16.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, Guobang Pharma ranks better than 61.13% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-30), Guobang Pharma's share price is ¥16.30. Guobang Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was ¥11.14. Hence, Guobang Pharma's PB Ratio of today is 1.46.
Good Sign:
Guobang Pharma Ltd stock PB Ratio (=1.39) is close to 1-year low of 1.32.
The historical rank and industry rank for Guobang Pharma's PB Ratio or its related term are showing as below:
SHSE:605507'
s PB Ratio Range Over the Past 10 Years
Min: 1.06 Med: 1.61 Max: 5.51
Current: 1.46
During the past 9 years, Guobang Pharma's highest PB Ratio was 5.51. The lowest was 1.06. And the median was 1.61.
SHSE:605507's PB Ratio is ranked better than 61.13% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs SHSE:605507: 1.46
During the past 12 months, Guobang Pharma's average Book Value Per Share Growth Rate was 5.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 14.50% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Guobang Pharma was 62.90% per year. The lowest was 6.10% per year. And the median was 28.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Guobang Pharma PB Ratio Related Terms
Guobang Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Guobang Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guobang Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Guobang Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Guobang Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Guobang Pharma (SHSE:605507) has a PB Ratio of 1.46 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Guobang Pharma and its competitors. This is near median its historical median of 1.61. Over the past decade, Guobang Pharma's PB Ratio has ranged from 1.06 to 5.51. According to the industry distribution chart, Guobang Pharma ranks #358 out of 921 companies in the Drug Manufacturers industry, placing it in the top 38.9%.
Is Guobang Pharma's PB Ratio too high?
Guobang Pharma's current PB Ratio of 1.46 is near median its 10-year median of 1.61. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 5.51. The Drug Manufacturers industry median PB Ratio is 1.86. Guobang Pharma's value of 1.46 is 21.5% below this industry median. Based on the distribution chart, Guobang Pharma ranks #358 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guobang Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Guobang Pharma ranks #358 out of 921 companies for PB Ratio. This puts Guobang Pharma in the upper half of its industry. The industry median PB Ratio is 1.86. Guobang Pharma's value of 1.46 is 21.5% below this benchmark. Historically, Guobang Pharma's own PB Ratio has ranged from 1.06 to 5.51 over the past decade. While the company's 10-year median is 1.61 vs. the industry median of 1.86, Guobang Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guobang Pharma's current PB Ratio of 1.46 is 21.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Guobang Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guobang Pharma's current PB Ratio is 1.46, which is near median its own 10-year median of 1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.00, compared to a current price of ¥16.30 — trading 1.9% above its estimated fair value. The current PB Ratio is 1.46, which is near median its 10-year median of 1.61 and 21.5% below the Drug Manufacturers industry median of 1.86. Guobang Pharma's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current PB Ratio is 1.46 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guobang Pharma (SHSE:605507) Overvalued in 2026?
Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued.
The current stock price of ¥16.30 is trading 1.9% above its estimated GF Value™ of ¥16.00.
GuruFocus considers Guobang Pharma to be Fairly Valued.
Key valuation signals for SHSE:605507:
PB Ratio: 1.46 (near median its 10-year median of 1.61)
GF Value™: ¥16.00 vs. price of ¥16.30 (1.9% above fair value)
Industry Position: 21.5% below the Drug Manufacturers median (#358 of 921)
No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
88GF Score
Get the complete analysis for SHSE:605507
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605507 has been successfully added to your 
